Akari Therapeutics, Plc Revenue
Akari Therapeutics, Plc (AKTX) reported Revenue of $0 for the 3-month period ending 2024-06-30, per its 8-K filed 2024-09-06.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2024-09-06
- Akari Therapeutics, Plc revenue from contract with customer, excluding assessed tax for the quarter ending 2024-06-30 was $0.00.
- Akari Therapeutics, Plc revenue from contract with customer, excluding assessed tax for the quarter ending 2023-06-30 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|
| 2024-06-30 | $0.00 8-K · filed 2024-09-06 | $0.00 8-K · filed 2024-09-06 | |
| 2023-12-31 | $367.88K 8-K · filed 2024-09-06 | ||
| 2023-06-30 | $0.00 8-K · filed 2024-09-06 | $13.85K 8-K · filed 2024-09-06 | |
| 2022-12-31 | $607.68K 8-K · filed 2024-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |